Implication of 2-18Fluor-2-Deoxyglucose Positron Emission Tomography in the Follow-Up of Hürthle Cell Thyroid Cancer
- 1 February 2002
- journal article
- research article
- Published by Mary Ann Liebert Inc in Thyroid®
- Vol. 12 (2) , 155-161
- https://doi.org/10.1089/105072502753522392
Abstract
The aim of this retrospective study was to investigate the value of positron emission tomography (PET) with 2-18fluor-2-deoxy-glucose (FDG) in the follow-up of Hürthle cell thyroid cancer (HTC), a rare variant of thyroid malignancies. FDG-PET studies were performed in 17 patients with HTC. In subgroup A (n = 13) PET was initiated because of an elevated thyroglobulin (Tg) level whereas in subgroup B (n = 4) the study was performed to evaluate suspect findings of morphologic imaging while Tg remained undetectable. Pathologically increased FDG uptake was found in all patients of subgroup A. In 10 studies, PET results were proven as true-positive either by surgery or by morphologic imaging. One study was false-positive. Final evaluation was not possible in two cases. In subgroup B, PET was true-negative in three and false-positive in one patient. For the detection of recurrent HTC by means of FDG-PET a meta-analysis including data of a multicenter study revealed an overall sensitivity of 92%, a specificity of 80%, a positive predictive value of 92%, and a negative predictive value of 80% while the accuracy was 89%. This study supports the efficiency of FDG-PET in the follow-up of HTC.Keywords
This publication has 22 references indexed in Scilit:
- Expectation maximization reconstruction of positron emission tomography images using anatomical magnetic resonance informationIEEE Transactions on Medical Imaging, 1997
- Thyroid cancer: differentiated carcinomaCancer Treatment Reviews, 1996
- IMAGING IN THYROID CANCEREndocrinology and Metabolism Clinics of North America, 1996
- Redifferentiation therapy of differentiated thyroid carcinoma with retinoic acid: basics and first clinical resultsExperimental and Clinical Endocrinology & Diabetes, 1996
- Clinical utility of technetium-99m methoxisobutylisonitrile imaging in differentiated thyroid carcinoma: comparison with thallium-201 and iodine-131 Na scintigraphy, and serum thyroglobulin quantitationEuropean Journal of Nuclear Medicine and Molecular Imaging, 1995
- Management considerations in Hürthle cell carcinomaSurgery, 1995
- The role of technetium-99m sestamibi whole-body scans in diagnosing metastatic Hurthle cell carcinoma of the thyroid gland after total thyroidectomy: a comparison with iodine-131 and thallium-201 whole-body scansEuropean Journal of Nuclear Medicine and Molecular Imaging, 1994
- Expression of insulin-like growth factor 1 (IGF-1) in the bovine oviduct during the oestrous cycleExperimental and Clinical Endocrinology & Diabetes, 1994
- Invasive Hürthle Cell Carcinoma of the Thyroid: Natural History and ManagementMayo Clinic Proceedings, 1984